Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-09-30 17:36:13 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: DOI: 10.1016/S2468-1253(24)00095-5
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125324000955
其他信息:
出版社: Elsevier BV
作者: Do-Youn Oh; Aiwu Ruth He; Mohamed Bouattour; Takuji Okusaka; Shukui Qin; Li-Tzong Chen; Masayuki Kitano; Choong-kun Lee; Jin Won Kim; Ming-Huang Chen; Thatthan Suksombooncharoen; Masafumi Ikeda; Myung Ah Lee; Jen-Shi Chen; Piotr Potemski; Howard A Burris; Vikas Ostwal; Suebpong Tanasanvimon; Chigusa Morizane; Renata E Zaucha; Mairéad G McNamara; Antonio Avallone; Juan E Cundom; Valeriy Breder; Benjamin Tan; Satoshi Shimizu; David Tougeron; Ludovic Evesque; Mila Petrova; David B Zhen; Roopinder Gillmore; Vineet Govinda Gupta; Farshid Dayyani; Joon Oh Park; Gary L Buchschacher; Felipe Rey; Hyosung Kim; Julie Wang; Claire Morgan; Nana Rokutanda; Magdalena Żotkiewicz; Arndt Vogel; Juan W Valle
